TGW101 / Tagworks - LARVOL DELTA

Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101… (Canada Newswire) - "Tagworks Pharmaceuticals BV...announced the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for a Phase 1 clinical trial evaluating TGW101, a first-in-class antibody drug-conjugate (ADC) targeting tumor associated glycoprotein 72 (TAG-72) with an monomethyl auristatin E (MMAE) payload, in patients with advanced solid tumors....Tagworks initiated first-in-human Phase 1 clinical development of TGW101 in a multicenter, open-label, dose-escalation trial in patients with advanced solid tumors."

IND • New P1 trial • Oncology • Solid Tumor

Preclinical development of TGW101, a first in class click-cleavable ADC with MMAE against non-internalizing pan-carcinoma marker TAG72 (AACR 2025) - "In conclusion, TGW101 demonstrated potent and specific in vitro and in vivo anti-tumor activity, while it was well tolerated in rats and NHPs at doses at or higher than current MMAE ADCs. This warrants clinical development of this promising click-cleavable ADC with the aim to expand the ADC target scope."

Preclinical • Oncology • Solid Tumor • TAG-72

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Tagworks Pharmaceuticals BV

New P1 trial • Solid Tumor

Tagworks Pharmaceuticals Announces $65 Million in Series A Financing to Advance Click-to-Release Therapeutics (PRNewswire-Asia) - "Tagworks Pharmaceuticals BV...announced a $65 million Series A financing led by Ysios Capital and Gilde Healthcare with participation from Novartis Venture Fund, New Enterprise Associates (NEA), and Lightstone Ventures....The financing will support the advancement of TGW101, Tagworks' lead click-cleavable ADC program, and the company's proprietary Click-to-Release platform....The company's lead program, TGW101, is a click-cleavable ADC targeting tumor-associated glycoprotein 72 (TAG72), a clinically validated non-internalizing target widely expressed in solid tumors."

Financing • Oncology • Solid Tumor